MicroRNA-205-5p regulates the chemotherapeutic resistance of hepatocellular carcinoma cells by targeting PTEN/JNK/ANXA3 pathway

Hepatocellular carcinoma (HCC) is a common malignant tumor of the digestive system, and patients with advanced HCC have a poor outlook, partly due to resistance to chemotherapeutic drugs. Previous studies have implicated microRNAs in the regulation of chemoresistance, and we have previously shown th...

Full description

Saved in:
Bibliographic Details
Published inAmerican journal of translational research Vol. 9; no. 9; pp. 4300 - 4307
Main Authors Shao, Ping, Qu, Wei-Kun, Wang, Cheng-Ye, Tian, Yu, Ye, Ming-Liang, Sun, De-Guang, Sui, Ji-Dong, Wang, Li-Ming, Fan, Rong, Gao, Zhen-Ming
Format Journal Article
LanguageEnglish
Published United States e-Century Publishing Corporation 01.01.2017
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Hepatocellular carcinoma (HCC) is a common malignant tumor of the digestive system, and patients with advanced HCC have a poor outlook, partly due to resistance to chemotherapeutic drugs. Previous studies have implicated microRNAs in the regulation of chemoresistance, and we have previously shown that microRNA (miR)-205-5p is down-regulated in multiple hepatoma cell lines. Here, we investigate whether miR-205-5p is involved in chemotherapeutic resistance in HCC. Expression of miR-205-5p was measured by real-time quantitative reverse transcription PCR and cell viability was determined using a CCK-8 cell viability assay. Expression of proteins in the PTEN/JNK/ANXA3 pathway were assessed via Western blotting. We found that miR-205-5p expression was down-regulated in all HCC cell lines investigated. In addition, miR-205-5p expression was upregulated by 5-fluorouracil (5-Fu) treatment in Bel-7402 (Bel) cells. Interestingly, miR-205-5p expression was increased in multidrug-resistant Bel-7402/5-Fu (Bel/Fu) cells, compared with Bel cells. We next demonstrated that sensitivity to 5-Fu was increased in Bel/Fu cells after treatment with a miR-205-5p inhibitor. Similarly, increased resistance to 5-Fu was observed in Bel cells after transfection with a miR-205-5p mimic. We injected nude mice with Bel/5-Fu cells to promote tumor growth, and found that co-treatment with a miR-205-5p antagomir and 5-Fu slowed tumor growth more than either treatment alone. Finally, we found that these effects were all associated with changes in the PTEN/JNK/ANXA3 pathway. In conclusion, inhibition of miR-205-5p may reverse chemotherapeutic resistance to 5-Fu, and this may occur via the PTEN/JNK/ANXA3 pathway.
AbstractList Hepatocellular carcinoma (HCC) is a common malignant tumor of the digestive system, and patients with advanced HCC have a poor outlook, partly due to resistance to chemotherapeutic drugs. Previous studies have implicated microRNAs in the regulation of chemoresistance, and we have previously shown that microRNA (miR)-205-5p is down-regulated in multiple hepatoma cell lines. Here, we investigate whether miR-205-5p is involved in chemotherapeutic resistance in HCC. Expression of miR-205-5p was measured by real-time quantitative reverse transcription PCR and cell viability was determined using a CCK-8 cell viability assay. Expression of proteins in the PTEN/JNK/ANXA3 pathway were assessed via Western blotting. We found that miR-205-5p expression was down-regulated in all HCC cell lines investigated. In addition, miR-205-5p expression was upregulated by 5-fluorouracil (5-Fu) treatment in Bel-7402 (Bel) cells. Interestingly, miR-205-5p expression was increased in multidrug-resistant Bel-7402/5-Fu (Bel/Fu) cells, compared with Bel cells. We next demonstrated that sensitivity to 5-Fu was increased in Bel/Fu cells after treatment with a miR-205-5p inhibitor. Similarly, increased resistance to 5-Fu was observed in Bel cells after transfection with a miR-205-5p mimic. We injected nude mice with Bel/5-Fu cells to promote tumor growth, and found that co-treatment with a miR-205-5p antagomir and 5-Fu slowed tumor growth more than either treatment alone. Finally, we found that these effects were all associated with changes in the PTEN/JNK/ANXA3 pathway. In conclusion, inhibition of miR-205-5p may reverse chemotherapeutic resistance to 5-Fu, and this may occur via the PTEN/JNK/ANXA3 pathway.
Hepatocellular carcinoma (HCC) is a common malignant tumor of the digestive system, and patients with advanced HCC have a poor outlook, partly due to resistance to chemotherapeutic drugs. Previous studies have implicated microRNAs in the regulation of chemoresistance, and we have previously shown that microRNA (miR)-205-5p is down-regulated in multiple hepatoma cell lines. Here, we investigate whether miR-205-5p is involved in chemotherapeutic resistance in HCC. Expression of miR-205-5p was measured by real-time quantitative reverse transcription PCR and cell viability was determined using a CCK-8 cell viability assay. Expression of proteins in the PTEN/JNK/ANXA3 pathway were assessed via Western blotting. We found that miR-205-5p expression was down-regulated in all HCC cell lines investigated. In addition, miR-205-5p expression was upregulated by 5-fluorouracil (5-Fu) treatment in Bel-7402 (Bel) cells. Interestingly, miR-205-5p expression was increased in multidrug-resistant Bel-7402/5-Fu (Bel/Fu) cells, compared with Bel cells. We next demonstrated that sensitivity to 5-Fu was increased in Bel/Fu cells after treatment with a miR-205-5p inhibitor. Similarly, increased resistance to 5-Fu was observed in Bel cells after transfection with a miR-205-5p mimic. We injected nude mice with Bel/5-Fu cells to promote tumor growth, and found that co-treatment with a miR-205-5p antagomir and 5-Fu slowed tumor growth more than either treatment alone. Finally, we found that these effects were all associated with changes in the PTEN/JNK/ANXA3 pathway. In conclusion, inhibition of miR-205-5p may reverse chemotherapeutic resistance to 5-Fu, and this may occur via the PTEN/JNK/ANXA3 pathway.Hepatocellular carcinoma (HCC) is a common malignant tumor of the digestive system, and patients with advanced HCC have a poor outlook, partly due to resistance to chemotherapeutic drugs. Previous studies have implicated microRNAs in the regulation of chemoresistance, and we have previously shown that microRNA (miR)-205-5p is down-regulated in multiple hepatoma cell lines. Here, we investigate whether miR-205-5p is involved in chemotherapeutic resistance in HCC. Expression of miR-205-5p was measured by real-time quantitative reverse transcription PCR and cell viability was determined using a CCK-8 cell viability assay. Expression of proteins in the PTEN/JNK/ANXA3 pathway were assessed via Western blotting. We found that miR-205-5p expression was down-regulated in all HCC cell lines investigated. In addition, miR-205-5p expression was upregulated by 5-fluorouracil (5-Fu) treatment in Bel-7402 (Bel) cells. Interestingly, miR-205-5p expression was increased in multidrug-resistant Bel-7402/5-Fu (Bel/Fu) cells, compared with Bel cells. We next demonstrated that sensitivity to 5-Fu was increased in Bel/Fu cells after treatment with a miR-205-5p inhibitor. Similarly, increased resistance to 5-Fu was observed in Bel cells after transfection with a miR-205-5p mimic. We injected nude mice with Bel/5-Fu cells to promote tumor growth, and found that co-treatment with a miR-205-5p antagomir and 5-Fu slowed tumor growth more than either treatment alone. Finally, we found that these effects were all associated with changes in the PTEN/JNK/ANXA3 pathway. In conclusion, inhibition of miR-205-5p may reverse chemotherapeutic resistance to 5-Fu, and this may occur via the PTEN/JNK/ANXA3 pathway.
Author Qu, Wei-Kun
Ye, Ming-Liang
Wang, Li-Ming
Shao, Ping
Fan, Rong
Tian, Yu
Sun, De-Guang
Sui, Ji-Dong
Gao, Zhen-Ming
Wang, Cheng-Ye
Author_xml – sequence: 1
  givenname: Ping
  surname: Shao
  fullname: Shao, Ping
  organization: Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, The Second Affiliated Hospital of Dalian Medical UniversityDalian, China
– sequence: 2
  givenname: Wei-Kun
  surname: Qu
  fullname: Qu, Wei-Kun
  organization: Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, The Second Affiliated Hospital of Dalian Medical UniversityDalian, China
– sequence: 3
  givenname: Cheng-Ye
  surname: Wang
  fullname: Wang, Cheng-Ye
  organization: Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, The Second Affiliated Hospital of Dalian Medical UniversityDalian, China
– sequence: 4
  givenname: Yu
  surname: Tian
  fullname: Tian, Yu
  organization: Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, The Second Affiliated Hospital of Dalian Medical UniversityDalian, China
– sequence: 5
  givenname: Ming-Liang
  surname: Ye
  fullname: Ye, Ming-Liang
  organization: Key Laboratory of Separation Science for Analytical Chemistry, Dalian Institute of Chemical Physics, Chinese Academy of SciencesDalian, China
– sequence: 6
  givenname: De-Guang
  surname: Sun
  fullname: Sun, De-Guang
  organization: Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, The Second Affiliated Hospital of Dalian Medical UniversityDalian, China
– sequence: 7
  givenname: Ji-Dong
  surname: Sui
  fullname: Sui, Ji-Dong
  organization: Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, The Second Affiliated Hospital of Dalian Medical UniversityDalian, China
– sequence: 8
  givenname: Li-Ming
  surname: Wang
  fullname: Wang, Li-Ming
  organization: Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, The Second Affiliated Hospital of Dalian Medical UniversityDalian, China
– sequence: 9
  givenname: Rong
  surname: Fan
  fullname: Fan, Rong
  organization: VIP Ward No. 2, The Second Affiliated Hospital of Dalian Medical UniversityDalian, China
– sequence: 10
  givenname: Zhen-Ming
  surname: Gao
  fullname: Gao, Zhen-Ming
  organization: Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, The Second Affiliated Hospital of Dalian Medical UniversityDalian, China
BackLink https://www.ncbi.nlm.nih.gov/pubmed/28979703$$D View this record in MEDLINE/PubMed
BookMark eNpVUEtLxDAQLqKoq_4FydFL2Ty2yfYiLOJ7XUUUvJVpdrKNtE1NUmVP_nUrPtDTfMx8D-YbJZuta3Ej2WX5RKRTNmGbf_BOMgrhmVKZ5ZJvJzt8mqtcUbGbvN9Y7d39YpZymqVZRzyu-hoiBhIrJLrCxg3AQ4d9tHo4BxsitBqJM6TCDqLTWNeDxhMNXtvWNUA-V4GUaxLBrzDadkXuHk4X46vF9Xi2eJoJMgirN1jvJ1sG6oAH33MveTw7fTi5SOe355cns3nacSljyjg3iuuJWiJkUgMFaqa5AGGmitIcuZwILBkzzJRSLalUOluiVEYzk-lSiL3k-Mu368sGlxrb6KEuOm8b8OvCgS3-X1pbFSv3WmSSc674YHD0beDdS48hFo0Nn29Ci64PxdC1kkwM7IF6-DfrN-SndfEBRAKDMQ
ContentType Journal Article
Copyright AJTR Copyright © 2017 2017
Copyright_xml – notice: AJTR Copyright © 2017 2017
DBID NPM
7X8
5PM
DatabaseName PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle PubMed
MEDLINE - Academic
DatabaseTitleList
PubMed
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1943-8141
EndPage 4307
ExternalDocumentID PMC5622272
28979703
Genre Journal Article
GroupedDBID ---
23M
2WC
53G
ADBBV
AEGXH
AENEX
ALMA_UNASSIGNED_HOLDINGS
BAWUL
C1A
DIK
F5P
GX1
HYE
NPM
OK1
OVT
RNS
RPM
TR2
7X8
5PM
ID FETCH-LOGICAL-p266t-122f72c47dea56ca0a0f893a3f87009e2643eb11f1fb67d067c5de67fc1f5cb33
ISSN 1943-8141
IngestDate Thu Aug 21 14:12:28 EDT 2025
Fri Jul 11 16:48:28 EDT 2025
Mon Aug 18 08:05:16 EDT 2025
IsPeerReviewed false
IsScholarly true
Issue 9
Keywords PTEN
MicroRNA-205
chemotherapeutic resistance
hepatocellular carcinoma
Language English
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-p266t-122f72c47dea56ca0a0f893a3f87009e2643eb11f1fb67d067c5de67fc1f5cb33
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Equal contributors.
PMID 28979703
PQID 1947613622
PQPubID 23479
PageCount 8
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_5622272
proquest_miscellaneous_1947613622
pubmed_primary_28979703
PublicationCentury 2000
PublicationDate 2017-01-01
PublicationDateYYYYMMDD 2017-01-01
PublicationDate_xml – month: 01
  year: 2017
  text: 2017-01-01
  day: 01
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle American journal of translational research
PublicationTitleAlternate Am J Transl Res
PublicationYear 2017
Publisher e-Century Publishing Corporation
Publisher_xml – name: e-Century Publishing Corporation
References 26095609 - Stem Cell Reports. 2015 Jul 14;5(1):45-59
19244118 - Cancer Res. 2009 Mar 15;69(6):2287-95
22189913 - J Cell Biochem. 2012 May;113(5):1671-80
21546262 - Crit Rev Oncol Hematol. 2012 Feb;81(2):103-22
24339740 - Neoplasia. 2013 Nov;15(11):1282-91
21454583 - J Biol Chem. 2011 May 13;286(19):16606-14
18199536 - Cancer Res. 2008 Jan 15;68(2):425-33
18546601 - Nat Protoc. 2008;3(6):1101-8
25220842 - Int J Cancer. 2015 Mar 1;136(5):E359-86
19135886 - Cell. 2009 Jan 9;136(1):26-36
25763354 - Front Oncol. 2015 Feb 16;5:24
21802841 - Cancer Lett. 2011 Nov 28;310(2):160-9
26807189 - Am J Transl Res. 2015 Nov 15;7(11):2433-41
16557279 - Nat Rev Cancer. 2006 Apr;6(4):259-69
27379838 - Leuk Res. 2016 Aug;47:172-7
24375474 - Mol Carcinog. 2015 Aug;54(8):598-607
16251533 - N Engl J Med. 2005 Oct 27;353(17):1768-71
21330408 - Cancer Res. 2011 Apr 1;71(7):2611-21
25544773 - Oncotarget. 2015 Feb 10;6(4):2302-14
20405329 - Ann Surg Oncol. 2010 May;17(5):1247-56
25973003 - Int J Clin Exp Pathol. 2015 Feb 01;8(2):1175-83
16929323 - Nat Rev Cancer. 2006 Sep;6(9):674-87
26711784 - Tumour Biol. 2016 Jun;37(6):8007-18
14744438 - Cell. 2004 Jan 23;116(2):281-97
25929864 - Curr Protein Pept Sci. 2015;16(4):301-9
24084898 - Oncol Rep. 2013 Dec;30(6):2897-902
24145123 - Mol Oncol. 2014 Feb;8(1):83-92
19238171 - Cell Res. 2009 Apr;19(4):439-48
19646254 - Mol Cancer. 2009 Jul 31;8:56
References_xml – reference: 19244118 - Cancer Res. 2009 Mar 15;69(6):2287-95
– reference: 21546262 - Crit Rev Oncol Hematol. 2012 Feb;81(2):103-22
– reference: 22189913 - J Cell Biochem. 2012 May;113(5):1671-80
– reference: 21454583 - J Biol Chem. 2011 May 13;286(19):16606-14
– reference: 25973003 - Int J Clin Exp Pathol. 2015 Feb 01;8(2):1175-83
– reference: 26807189 - Am J Transl Res. 2015 Nov 15;7(11):2433-41
– reference: 25763354 - Front Oncol. 2015 Feb 16;5:24
– reference: 16929323 - Nat Rev Cancer. 2006 Sep;6(9):674-87
– reference: 21802841 - Cancer Lett. 2011 Nov 28;310(2):160-9
– reference: 18546601 - Nat Protoc. 2008;3(6):1101-8
– reference: 26095609 - Stem Cell Reports. 2015 Jul 14;5(1):45-59
– reference: 24145123 - Mol Oncol. 2014 Feb;8(1):83-92
– reference: 16557279 - Nat Rev Cancer. 2006 Apr;6(4):259-69
– reference: 14744438 - Cell. 2004 Jan 23;116(2):281-97
– reference: 24375474 - Mol Carcinog. 2015 Aug;54(8):598-607
– reference: 20405329 - Ann Surg Oncol. 2010 May;17(5):1247-56
– reference: 18199536 - Cancer Res. 2008 Jan 15;68(2):425-33
– reference: 24084898 - Oncol Rep. 2013 Dec;30(6):2897-902
– reference: 25929864 - Curr Protein Pept Sci. 2015;16(4):301-9
– reference: 16251533 - N Engl J Med. 2005 Oct 27;353(17):1768-71
– reference: 19238171 - Cell Res. 2009 Apr;19(4):439-48
– reference: 21330408 - Cancer Res. 2011 Apr 1;71(7):2611-21
– reference: 27379838 - Leuk Res. 2016 Aug;47:172-7
– reference: 26711784 - Tumour Biol. 2016 Jun;37(6):8007-18
– reference: 24339740 - Neoplasia. 2013 Nov;15(11):1282-91
– reference: 19646254 - Mol Cancer. 2009 Jul 31;8:56
– reference: 19135886 - Cell. 2009 Jan 9;136(1):26-36
– reference: 25220842 - Int J Cancer. 2015 Mar 1;136(5):E359-86
– reference: 25544773 - Oncotarget. 2015 Feb 10;6(4):2302-14
SSID ssj0065962
Score 2.2671807
Snippet Hepatocellular carcinoma (HCC) is a common malignant tumor of the digestive system, and patients with advanced HCC have a poor outlook, partly due to...
SourceID pubmedcentral
proquest
pubmed
SourceType Open Access Repository
Aggregation Database
Index Database
StartPage 4300
SubjectTerms Original
Title MicroRNA-205-5p regulates the chemotherapeutic resistance of hepatocellular carcinoma cells by targeting PTEN/JNK/ANXA3 pathway
URI https://www.ncbi.nlm.nih.gov/pubmed/28979703
https://www.proquest.com/docview/1947613622
https://pubmed.ncbi.nlm.nih.gov/PMC5622272
Volume 9
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3Pb9MwGLXKDogL4jdlgIzEbQpLYsdWjlU1NDE1qqAT3alyHJtWWtNoTYTYhf-Ev5XPTuK61Q6wS5Q6aRT5vfh7fvnyGaGPVAOosYDnm0U6oDlRQcqSOCgKBmpbSsqksQYmGTu_pF_myXww-ONlLTV1_kne3vldyX1QhTbA1Xwl-x_IuotCA-wDvrAFhGH7TxhPTDbd12wEt5sESXVy0y4sb6o2APoAx9r_vgoOb41aNI-ylYgVTLiNcW8zUaVZVKjcrMWJadpaWWqzxI2XMJ2dZWYx5-zC1F_I5iNiCrIuf4q9l8Lu7Y9XjqI2sfC6dxy70kLOgv62FNaqnfYB1FqwNu9PrYKLxjH3e2drj5eq_BFcOTbOVq2Be9X49kXED-wLFYzb4Orbbn0R556Zqh2bU0qMYxn5g3fqcTT1BmJKwtAL6vCT-wEDcKzWlhUw4eQpD8kuHrosxelkDOowjjmE-Ackor0X1MZ5ZtYtMrWkuwvcNUU5zLT1pMvsCXrczTnwqCXQUzRQ5TP0cNJlVTxHvw94hB2PMNAHH_II73iENxrv8wg7HmHLI5z_wo5H2PDoFFh0ajmEOw69QJefz2bj86BbmCOoQM_VQRTHmseS8kKJhEkRilCD7hVEw-gfpgpENgENEOlI54wXIIhkUijGtYx0InNCXqKjclOq1whTKgqY0sYq54xKrlJR8LBImcwlhXOLIfrQ9-oCBj5z56JUm2a7ADpw0KIA0BC9ant5UbUVWhY9JkPE9_rfnWCKqu8fKVdLW1y9Q_zNvf95jB7teP4WHdU3jXoHwrXO31v-_AU-nKcz
linkProvider National Library of Medicine
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=MicroRNA-205-5p+regulates+the+chemotherapeutic+resistance+of+hepatocellular+carcinoma+cells+by+targeting+PTEN%2FJNK%2FANXA3+pathway&rft.jtitle=American+journal+of+translational+research&rft.au=Shao%2C+Ping&rft.au=Qu%2C+Wei-Kun&rft.au=Wang%2C+Cheng-Ye&rft.au=Tian%2C+Yu&rft.date=2017-01-01&rft.pub=e-Century+Publishing+Corporation&rft.eissn=1943-8141&rft.volume=9&rft.issue=9&rft.spage=4300&rft.epage=4307&rft_id=info%3Apmid%2F28979703&rft.externalDocID=PMC5622272
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1943-8141&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1943-8141&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1943-8141&client=summon